ACT Brief: Natural History Data Matching Challenges, Execution Translation Gap in Trials, and Accelerated Approval Pathway Reforms

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In part four of her video interview, Mwango Kashoki, MD, MPH, senior vice president and global head of regulatory strategy at Parexel, discussed how heterogeneity in disease course and patient characteristics creates confounding risk when using natural history data as external controls. Achieving meaningful patient matching requires rigorous methodology and clear understanding of what variables drive disease progression versus treatment effect.
• In a new contributed article from Tufts, the execution translation gap—the failure to convert identified problems into coordinated action—costs millions per trial through delayed amendments, persistent deviations, and slow site activation. Despite advances in dashboards and real-time monitoring, organizations struggle with fragmented accountability, misaligned incentives, and process rigidity that prevent agile response to emerging issues.
• ICER released a white paper on FDA's accelerated approval pathway recommending reforms including better surrogate endpoint validation, greater regulatory transparency, informed consent requirements, and evidence-tied pricing models. The report highlights persistent challenges with regulatory consistency, delayed confirmatory trials, and access restrictions, calling for stronger accountability mechanisms to preserve the pathway's credibility.

That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.